Olanzapine (Zoulan)

Zoulan - Olanzapine (5mg/10mg Tablets)

ZOULAN – Olanzapine (5mg/10mg Tablets)

Olanzapine is an atypical antipsychotic. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder.

Overview

  • Olanzapine sustain a better treatment response in comparison to Risperidone1
  • Switch from Risperidone to Olanzapine leads to significant improvement in clinical and functional outcomes1
  • Consistently greater reductions in severity of the illness and negative symptoms were seen with olanzapine1
  • Olanzapine improved the general mental state (PANSS score) better than risperidone1
  • Olanzapine showed a significant advantage over risperidone in improving negative symptoms and overall clinical severity1
  • Olanzepine has been shown to be effective for the treatment of manic episodes in bipolar disorder2
  • Olanzapine monotherapy had a significantly greater treatment response, than the placebo group (52.5% vs 43.3%, P=0.05) for the treatment of depressive episodes in bipolar I disorder2
  • Olanzapine is effective for the treatment of the depressive phase of bipolar I disorder both in combination with antidepressants and as monotherapy2

Ref:

1. Indian Journal of Psychiatry, Jul-Sep 2016; 58(3):311-16

2. Neuropsychiatric Disease and Treatment 2016:12 2077–2087

Trials

  • Olanzapine restores procedural learning deficits and associated neural activity in schizophrenia1
  • Significant task-related activation changes were detected in the anterior cingulated extending to the precentral gyrus, superior frontal gyrus, middle frontal gyrus, insula and striatum1
  • This focused activation of PL-related regions possibly contributed to the PL-normalising effects of olanzapine1

Ref:

  1. 2015; 232:3135–3147

Mean procedural learning scores at baseline and follow-up in patients switched from typical antipsychotics to Risperidone and Olanzapine